Press Resease

Osteoporosis Drugs Market - Global Industry Analysis

Osteoporosis Drugs Market (Bisphosphonates, Calcitonin, Rank Ligand Inhibitors, Parathyroid Hormone Therapy (PTH) And Selective Estrogen Receptor Modulators (SERMs)) For Male And Female Population: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends, And Forecast, 2020 – 2028

Published Date: 29-Jun-2021 Category: Pharmaceutical Report Format : PDF Pages: 140 Report Code: ZMR-342 Status : Published

The global Osteoporosis Drugs Market accounted for USD 13.7 Billion in 2020 and is expected to reach USD 17.92 Billion by 2028, growing at a CAGR of around 3.3% between 2021 and 2028.

Description

Market Overview     

The global Osteoporosis Drugs Market accounted for USD 13.7 Billion in 2020 and is expected to reach USD 17.92 Billion by 2028, growing at a CAGR of around 3.3% between 2021 and 2028.   

The rampant increase in the elderly population alongside changing lifestyles impacting bone health is anticipated to support the expansion of the osteoporosis drugs market over the years ahead. Aside from this, growing incidences of osteoporosis witnessed in post-menopausal women are probably going to amplify the osteoporosis drugs market expansion within the near future.

Seemingly, various complications & side-effects like nausea, irritable bowel syndrome, stomach ulcers, and heartburn are witnessed within the patients after consumption of osteoporosis drugs. These side-effects are predicted to restrain the industry expansion over the forthcoming years. Nevertheless, the persistent focus of industry players on developing new drugs which will help in minimizing the side-effects and high investments in R&D activities concerning new drug discovery are likely to make new growth opportunities for the osteoporosis drugs market, thereby normalizing the impact of hindrances on the osteoporosis drugs market

COVID-19 Impact Analysis  

Besides, the COVID-19 outbreak, there's a drastic increase in the demand for medical facilities across the world. The increasing corona cases across the world are forcing governments of developed and emerging countries to extend their patient handling capacities. COVID-19 has delayed and disrupted the treatment of many patients with osteoporosis; hence, the American Society for Bone and Mineral Research (ASBMR) set up a steering committee of bone specialists to manage the treatment of targeted disorders amid the pandemic. The improvement in fundraising related to Osteoporosis Drugs Market is another major factor that will positively impact the market growth.

Growth Factors

The global Osteoporosis Drugs Market is propelled owing to the increase in the obese and geriatric population since these individuals are more apt to numerous persistent diseases. So, the obese and geriatric population needs care with security and ease. Also, the market is essentially driven by a big rise in the prevalence of this disorder globally. This unprecedented rise within the prevalence resulted in the high demand for drugs in prophylaxis and treatment of osteoporosis thus widening the expansion potential over the approaching years. Moreover, the geriatric population possessing high susceptibility for osteoporosis is further presumed to propel the high demand.

Report Scope:  

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Segment Analysis Preview  

Based on drug class the market is segmented into bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs). Key gender market covered under this study includes male and female. 

Rank ligand inhibitors are expected to grow at a lucrative CAGR during the forecast period. The high growth potential attained may be a consequence of positive patient outcomes related to rank ligand inhibitors. The positive patient outcomes are often attributed to significant improvements in bone metabolism. Rank ligand inhibitors also can be utilized in conjunction with other drugs to impart a synergistic effect in the overall treatment regime. The aforementioned factor is additionally predicted to be one of the key factors responsible to present lucrative opportunities. Other benefits concerning rank ligand Inhibitors like reduced cell bone turnover and increased bone mineral density, thereby implicating high demand.

Regional Analysis Preview

Regionally, North America has been leading the worldwide osteoporosis drugs market and is anticipated to continue on the dominant position within the years to return, states the market study. The presence of a well-established medical and healthcare infrastructure also as a drug delivery system is that the main factor behind the dominance of the North America osteoporosis drugs market. Additionally, sizable investments within the healthcare activities and favorable R&D policies of the govt towards the osteoporosis drug applications will further augment the osteoporosis drugs market growth.

Key Market Players & Competitive Landscape

The major players that are comprised in  Osteoporosis Drugs Market are  Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.

The global  Osteoporosis Drugs Market is segmented as follows:

By Drug Class

  • Bisphosphonates
  • Calcitonin 
  • Rank Ligand Inhibitors
  • Parathyroid Hormone Therapy (PTH) 
  • Selective Estrogen Receptor Modulators (SERMs)
  • Others

By Gender

  • Male
  • Female

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter No. 1 Introduction
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • Chapter No. 2 Executive Summary
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Drug Class
        • 2.1.1.2. Market Attractiveness Analysis, By Gender
        • 2.1.1.3. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Osteoporosis Drugs Market, 2016 – 2028 (USD Billion)
    • 2.4. Insights from Primary Respondents
  • Chapter No. 3 COVID 19 Impact Analysis
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • Chapter No. 4 Osteoporosis Drugs Market – Drug Class Segment Analysis
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Drug Class, 2020 & 2028
    • 4.2. Bisphosphonates
      • 4.2.1. Market Size and Forecast, By Region (USD Billion)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Selective Estrogen Receptor Modulators (SERMs)
      • 4.3.1. Market Size and Forecast, By Region (USD Billion)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Parathyroid Hormone Therapy (PTH)
      • 4.4.1. Market Size and Forecast, By Region (USD Billion)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Rank Ligand Inhibitors
      • 4.5.1. Market Size and Forecast, By Region (USD Billion)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.6. Calcitonin
      • 4.6.1. Market Size and Forecast, By Region (USD Billion)
      • 4.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.6.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.7. Others
      • 4.7.1. Market Size and Forecast, By Region (USD Billion)
      • 4.7.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.7.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 5 Osteoporosis Drugs Market – Gender Segment Analysis
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Gender, 2020 & 2028
    • 5.2. Male
      • 5.2.1. Market Size and Forecast, By Region (USD Billion)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Female
      • 5.3.1. Market Size and Forecast, By Region (USD Billion)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • Chapter No. 6 Plant Factory Grow Market – Region Segment Analysis
    • 6.1. Overview
      • 6.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 6.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Billion)
    • 6.2. North America
      • 6.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.2.2. North America Market Revenue, By Drug Class, 2016 – 2028
      • 6.2.3. North America Market Revenue, By Gender, 2016 – 2028
      • 6.2.5. U.S.
        • 6.2.5.1. U.S. Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.5.2. U.S. Market Revenue, By Gender, 2016 – 2028
      • 6.2.6. Canada
        • 6.2.6.1. Canada Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.6.2. Canada Market Revenue, By Gender, 2016 – 2028
      • 6.2.7. Mexico
        • 6.2.7.1. Mexico Market Revenue, By Drug Class, 2016 – 2028
        • 6.2.7.2. Mexico Market Revenue, By Gender, 2016 – 2028
    • 6.3. Europe
      • 6.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.3.2. Europe Market Revenue, By Drug Class, 2016 – 2028
      • 6.3.3. Europe Market Revenue, By Gender, 2016 – 2028
      • 6.3.5. Germany
        • 6.3.5.1. Germany Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.5.2. Germany Market Revenue, By Gender, 2016 – 2028
      • 6.3.6. France
        • 6.3.6.1. France Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.6.2. France Market Revenue, By Gender, 2016 – 2028
      • 6.3.7. U.K.
        • 6.3.7.1. U.K. Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.7.2. U.K. Market Revenue, By Gender, 2016 – 2028
      • 6.3.8. Italy
        • 6.3.8.1. Italy Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.8.2. Italy Market Revenue, By Gender, 2016 – 2028
      • 6.3.9. Spain
        • 6.3.9.1. Spain Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.9.2. Spain Market Revenue, By Gender, 2016 – 2028
      • 6.3.10. Rest of Europe
        • 6.3.10.1. Rest of Europe Market Revenue, By Drug Class, 2016 – 2028
        • 6.3.10.2. Rest of Europe Market Revenue, By Gender, 2016 – 2028
    • 6.4. Asia Pacific
      • 6.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.4.2. Asia Pacific Market Revenue, By Drug Class, 2016 – 2028
      • 6.4.3. Asia Pacific Market Revenue, By Gender, 2016 – 2028
      • 6.4.5. China
        • 6.4.5.1. China Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.5.2. China Market Revenue, By Gender, 2016 – 2028
      • 6.4.6. Japan
        • 6.4.6.1. Japan Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.6.2. Japan Market Revenue, By Gender, 2016 – 2028
      • 6.4.7. India
        • 6.4.7.1. India Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.7.2. India Market Revenue, By Gender, 2016 – 2028
      • 6.4.8. South Korea
        • 6.4.8.1. South Korea Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.8.2. South Korea Market Revenue, By Gender, 2016 – 2028
      • 6.4.9. South-East Asia
        • 6.4.9.1. South-East Asia Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.9.2. South-East Asia Market Revenue, By Gender, 2016 – 2028
      • 6.4.10. Rest of Asia Pacific
        • 6.4.10.1. Rest of Asia Pacific Market Revenue, By Drug Class, 2016 – 2028
        • 6.4.10.2. Rest of Asia Pacific Market Revenue, By Gender, 2016 – 2028
    • 6.5. Latin America
      • 6.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.5.2. Latin America Market Revenue, By Drug Class, 2016 – 2028
      • 6.5.3. Latin America Market Revenue, By Gender, 2016 – 2028
      • 6.5.5. Brazil
        • 6.5.5.1. Brazil Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.5.2. Brazil Market Revenue, By Gender, 2016 – 2028
      • 6.5.6. Argentina
        • 6.5.6.1. Argentina Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.6.2. Argentina Market Revenue, By Gender, 2016 – 2028
      • 6.5.7. Rest of Latin America
        • 6.5.7.1. Rest of Latin America Market Revenue, By Drug Class, 2016 – 2028
        • 6.5.7.2. Rest of Latin America Market Revenue, By Gender, 2016 – 2028
    • 6.6. The Middle-East and Africa
      • 6.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Billion)
      • 6.6.2. The Middle-East and Africa Market Revenue, By Drug Class, 2016 – 2028
      • 6.6.3. The Middle-East and Africa Market Revenue, By Gender, 2016 – 2028
      • 6.6.5. GCC Countries
        • 6.6.5.1. GCC Countries Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.5.2. GCC Countries Market Revenue, By Gender, 2016 – 2028
      • 6.6.6. South Africa
        • 6.6.6.1. South Africa Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.6.2. South Africa Market Revenue, By Gender, 2016 – 2028
      • 6.6.7. Rest of Middle-East Africa
        • 6.6.7.1. Rest of Middle-East Africa Market Revenue, By Drug Class, 2016 – 2028
        • 6.6.7.2. Rest of Middle-East Africa Market Revenue, By Gender, 2016 – 2028
  • Chapter No. 7: Osteoporosis Drugs Market – Industry Analysis
    • 7.1. Introduction
    • 7.2. Market Drivers
      • 7.2.1. Driving Factor 1 Analysis
      • 7.2.2. Driving Factor 2 Analysis
    • 7.3. Market Restraints
      • 7.3.1. Restraining Factor Analysis
    • 7.4. Market Opportunities
      • 7.4.1. Market Opportunity Analysis
    • 7.5. Porter’s Five Forces Analysis
    • 7.6. PEST Analysis
    • 7.7. Regulatory Landscape
    • 7.8. By Gender Landscape
    • 7.9. Regional Market Trends
      • 7.9.1. North America
      • 7.9.2. Europe
      • 7.9.3. Asia Pacific
      • 7.9.4. Latin America
      • 7.9.5. The Middle-East and Africa
    • 7.10. Pricing Analysis
    • 7.11. Value Chain Analysis
    • 7.12. Downstream Buyers
    • 7.13. Distributors/Traders List
  • Chapter No. 8: Competitive Landscape
    • 8.1. Company Market Share Analysis – 2019
      • 8.1.1. Global Osteoporosis Drugs Market: Company Market Share, 2019
      • 8.1.2. Global Osteoporosis Drugs Market, Company Market Revenue, 2016 – 2019 (USD Billion)
      • 8.1.3. Global Osteoporosis Drugs Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 8.1.4. Global Osteoporosis Drugs Market: Radar Determinant Chart, 2019
    • 8.2. Strategic Developments
      • 8.2.1. Acquisitions & Mergers
      • 8.2.2. New Product Launch
      • 8.2.3. Regional Expansion
    • 8.3. Company Strategic Developments – Heat Map Analysis
  • Chapter No. 9: Company Profiles
    • 9.1. Novartis International AG
      • 9.1.1. Company Overview
      • 9.1.2. Key Executives
      • 9.1.3. Product Portfolio
      • 9.1.4. Financial Overview
      • 9.1.5. Operating Business Segments
      • 9.1.6. Business Performance
      • 9.1.7. Recent Developments
    • 9.2. Eli Lilly Amgen Inc.
    • 9.3 Forteo
    • 9.4 Novo Nordisk A/S.
    • 9.5 F. Hoffmann La Roche Ltd.
    • 9.6 Company, Merck & Co, Inc.
    • 9.7 Actavis plc
    • 9.8 Pfizer, Inc
    • 9.9 Teva Pharmaceutical Industries Ltd.
    • 9.10 Company 10
  • Chapter No. 10: Marketing Strategy Analysis
    • 10.1. Marketing Channel
    • 10.2. Direct Marketing
    • 10.3. Indirect Marketing
    • 10.4. Marketing Channel Development Trends
    • 10.5. Economic/Pulitical Environmental Change
  • Chapter No. 11: Research Methodology
    • 11.1. Research Methodology
    • 11.2. Phase I - Secondary Research
    • 11.3. Phase II - Data Modeling
      • 11.3.1. Company Share Analysis Model
      • 11.3.2. Revenue Based Modeling
    • 11.4. Phase III - Primary Research
    • 11.5. Research Limitations
      • 11.5.1. Assumptions

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Drug Class
FIG NO. 2. Market Attractiveness Analysis, By Gender
FIG NO. 3. Market Attractiveness Analysis, By Region
FIG NO. 4. Global  Osteoporosis Drugs Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 5. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 6. Market Revenue Share, By Drug Class, 2020 & 2028 
FIG NO. 7. Global  Osteoporosis Drugs Market for Bisphosphonates, Revenue (USD Billion) 2016 – 2028
FIG NO. 8. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Bisphosphonates, By Country, 2020 & 2028
FIG NO. 9. Global  Osteoporosis Drugs Market for Selective Estrogen Receptor Modulators (SERMs), Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Selective Estrogen Receptor Modulators (SERMs), By Country, 2020 & 2028
FIG NO. 9. Global  Osteoporosis Drugs Market for Parathyroid Hormone Therapy (PTH) , Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Parathyroid Hormone Therapy (PTH) , By Country, 2020 & 2028
FIG NO. 11. Global  Osteoporosis Drugs Market for Rank Ligand Inhibitors, Revenue (USD Billion) 2016 – 2028
FIG NO. 12. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Rank Ligand Inhibitors, By Country, 2020 & 2028
FIG NO. 13. Global  Osteoporosis Drugs Market for Others, Revenue (USD Billion) 2016 – 2028
FIG NO. 14. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Others, By Country, 2020 & 2028
FIG NO. 15. Market Revenue Share, By Gender, 2020 & 2028
FIG NO. 16. Global  Osteoporosis Drugs Market for Male, Revenue (USD Billion) 2016 – 2028
FIG NO. 17. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Male, By Country, 2020 & 2028 
FIG NO. 18. Global  Osteoporosis Drugs Market for Female, Revenue (USD Billion) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Female, By Country, 2020 & 2028
FIG NO. 20. Global  Osteoporosis Drugs Market for Others, Revenue (USD Billion) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of  Osteoporosis Drugs Market for Others, By Country, 2020 & 2028
FIG NO. 22. Global  Osteoporosis Drugs Market Revenue Share, By Region, 2020 & 2028
FIG NO. 23. North America  Osteoporosis Drugs Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 24. Porter’s Five Forces Analysis for Global  Osteoporosis Drugs Market
FIG NO. 25. PEST Analysis for Global  Osteoporosis Drugs Market
FIG NO. 26. Pricing Analysis for Global  Osteoporosis Drugs Market
FIG NO. 27. Value Chain Analysis for Global  Osteoporosis Drugs Market
FIG NO. 28. Company Share Analysis, 2019
FIG NO. 29. Radar Determinant Chart, 2019
FIG NO. 30. Company Strategic Developments – Heat Map Analysis
FIG NO. 31. Business Segment Revenue Share, 2020 (%)
FIG NO. 32. Geographical Segment Revenue Share, 2020 (%)
FIG NO. 33. Market Channels
FIG NO. 34. Marketing Channel Development Trend
FIG NO. 35. Growth in World Gross Product, 2008-2018
FIG NO. 36. Research Methodology – Detailed View
FIG NO. 37. Research Methodology
 


List of Tables 

TABLE NO. 1. Global  Osteoporosis Drugs Market: Snapshot
TABLE NO. 2. Quarterly  Osteoporosis Drugs Market Revenue by Region, 2020
TABLE NO. 3. Quarterly  Osteoporosis Drugs Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion) 
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion) 
TABLE NO. 6. Global  Osteoporosis Drugs Market for Bisphosphonates, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global  Osteoporosis Drugs Market for Selective Estrogen Receptor Modulators (SERMs), by Region, 2016 – 2028 (USD Billion)
TABLE NO. 8. Global  Osteoporosis Drugs Market for Parathyroid Hormone Therapy (PTH) , by Region, 2016 – 2028 (USD Billion)
TABLE NO. 9. Global  Osteoporosis Drugs Market for Rank Ligand Inhibitors, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 10. Global  Osteoporosis Drugs Market for Others, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 11. Global  Osteoporosis Drugs Market for Male, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 12 Global  Osteoporosis Drugs Market for Female, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 13 Global  Osteoporosis Drugs Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 14. North America  Osteoporosis Drugs Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 15. North America  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 16. North America  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 17. U.S.  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 18. U.S.  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 19. Canada  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 20. Canada  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 21. Mexico  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 22. Mexico  Osteoporosis Drugs Market Revenue, By Drug Class, 2016 – 2028 (USD Billion)
TABLE NO. 23. Drivers for the  Osteoporosis Drugs Market: Impact Analysis
TABLE NO. 24. Restraints for the  Osteoporosis Drugs Market: Impact Analysis
TABLE NO. 25. Major Buyers of  Osteoporosis Drugs Market
TABLE NO. 26. Distributors/Traders List of  Osteoporosis Drugs Market
TABLE NO. 27. Global  Osteoporosis Drugs Market, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 28: Global  Osteoporosis Drugs Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)   


 

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Osteoporosis Drugs market. Zion Research has collected and analyzed key data belong to the global Osteoporosis Drugs market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Osteoporosis Drugs across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Osteoporosis Drugs industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Osteoporosis Drugs market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Osteoporosis is a bone disease, which may be due to lower than normal peak bone mass and greater than the normal bone loss. Osteoporosis may also occur due to a number of diseases or treatments such as anorexia, hyperthyroidism, alcoholism, surgical removal of the ovaries, and kidney disease. As a result, bones become weak and may break from a fall or, in serious cases, from sneezing or minor bumps.  Until a broken bone occurs there are typically no symptoms. Osteoporosis drugs are a kind of medicine for osteoporosis, including Zoledronic Acid (Reclast or Zometa) Fosamax, Actonel, Boniva and others.

The major driving factor for the global osteoporosis market is rapidly growing the geriatric population of the world coupled with changing lifestyle is impinging bone health. Furthermore, increasing the prevalence of osteoporosis in postmenopausal women and increasing investment in drug discovery and development is further expected to fuel the market growth in the years to come. Prevalence of osteoporosis is more common with age. Around 15% of white people in their 50s and 70% of those over 80 are affected by osteoporosis diseases. However, there are several side effects of osteoporosis drugs such as irritable bowel syndrome, heartburn, nausea, and ulcers in the stomach. Thus, side effects of osteoporosis drugs are expected to hamper the market growth over the next few years. Nevertheless, increasing investment in R&D for advanced development of new drugs and classes are expected open up new growth avenues within the forecast period.

The osteoporosis drugs market is segmented on the basis of different drug classes such as bisphosphonates, calcitonin, rank ligand inhibitors, parathyroid hormone therapy (PTH) and selective estrogen receptor modulators (SERMs).  Osteoporosis drugs market was dominated by the bisphosphonates segment, which accounted for significant revenue share in 2015. Bisphosphonates are commonly prescribed the drug for treatment and prevention of osteoporosis disease. Thus, this segment is expected to show strong growth in the near future. Tele-monitoring is another growing segment of this market. Parathyroid hormone therapy (PTH) was another growing segment of this market. Parathyroid hormone therapy (PTH) was another key segment and it expected to witness significant growth in the near future. Development of new drug classes such as PTH and RANK ligand inhibitors are projected to fuel the growth of osteoporosis drug market over the forecast period. Pipeline products such as odanacatib (cathepsin K inhibitor) and romosozumab are awaiting the approval and may contribute to driving the market growth in the years to come.

Based on gender, the market can be segmented into male and female. Osteoporosis is more common in female than male. The female segment accounted for the largest share in 2015. Increasing the prevalence of osteoporosis in postmenopausal women is driving the growth of the market. There are wide discrepancies between the incidence rate in women and men. Moreover, about 90% of the hip fractures occur in people over 50 years old.

North America was the largest regional market led by the U.S. and is projected to witness the highest growth within the forecast period owing to high investments in the healthcare industry, surging R&D initiatives and accessibility to the excellent infrastructure. Asia Pacific osteoporosis drugs market is expected to be the fastest-growing region in the years to come. Growth in this region will be mainly driven by factors such as rising aged population and increasing patient’s awareness pertaining to bone health. Latin America and the Middle East & Africa are also expected to experience significant growth of osteoporosis market in the years to come.

Some of the key participants in osteoporosis drug market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.  Major players are implementing sustainability strategies including product expansions, new product development and merger & acquisitions to gain the advantage over the competitors. For instance, drug maker Actavis Inc. agreed to acquire Warner Chilcott PLC for about USD5 billion in an all-stock deal aimed at enlarging Actavis's portfolio of specialty pharmaceutical brands—and shrinking its tax burden in 2013. Pipeline drugs of Merck and Pfizer cathepsin and aprela respectively are projected to provide the growth platform for these respective companies.


Frequently Asked Questions

The global  Osteoporosis Drugs Market was valued at USD 13.7 billion in 2020.

The global  Osteoporosis Drugs Market is expected to reach USD 17.9 billion by 2028, growing at a CAGR of 3.3% between 2021 to 2028.

Factors such as an unprecedented rise in the disease resulted in the high demand for drugs in prophylaxis and treatment of osteoporosis thus widening the growth potential over the coming years. Moreover, the geriatric population possessing high susceptibility for osteoporosis is further presumed to propel the high demand.

North America in 2020 ruled the  Osteoporosis Drugs Market and was believed to be the highest income-generating area all over the globe.  

The major players that are comprised in Osteoporosis Drugs Market are Novartis International AG, Eli Lilly Amgen Inc., Forteo, Novo Nordisk A/S., F. Hoffmann La Roche Ltd., and Company, Merck & Co, Inc., Actavis plc, Pfizer, Inc, and Teva Pharmaceutical Industries Ltd.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social